Novo Nordisk A/S (NYSE:NVO) slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results